From Tradition to Trend: Chinese Confinement Nannies Gain Popularity Across the U.S.
The centuries-old tradition of Chinese postpartum confinement is going mainstream in America, as more families seek culturally rooted newborn care and maternal recovery support.
LOS ANGELES, CA - August 15, 2025 - The centuries-old practice of zuo yue zi — or Chinese postpartum confinement — is no longer limited to the Asian community. Families across the United States are increasingly hiring Chinese confinement nannies to ensure mothers receive proper rest, nutrition, and newborn care during the critical first 30 to 100 days after birth.
'Postpartum care is about more than changing diapers — it's about a mother's physical healing, emotional stability, and family bonding,' said Stephanie Lin, founder of My Asian Nanny. 'We've seen a 40% increase in inquiries from non-Asian families over the past three years, especially in major metro areas.'
The growing interest reflects a wider shift in attitudes toward postpartum recovery, as more parents seek holistic and culturally informed support. Confinement nannies typically provide round-the-clock newborn care, traditional healing meals, lactation support, and gentle postpartum exercises to aid recovery.
The trend is supported by research showing that mothers who receive consistent postpartum care report faster physical recovery, lower stress levels, and a reduced risk of postpartum depression.
Parents can learn more or request a nanny by completing the Family Registration Intake Form.
About My Asian Nanny
My Asian Nanny is a U.S.-based referral agency specializing in postpartum confinement nannies and newborn care. Serving families nationwide, the agency connects clients with experienced caregivers who provide round-the-clock support, traditional postpartum meals, and expert newborn handling.
Media Contact
Company Name: My Asian Nanny
Contact Person: Stephanie Lin
Email: Send Email
Phone: 6269887577
Address: 216 west Garvey Avenue Unit G
City: Monterey Park
State: CA
Country: United States
Website: myasiannanny.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
15 hours ago
- Globe and Mail
From Tradition to Trend: Chinese Confinement Nannies Gain Popularity Across the U.S.
"A Chinese confinement nanny in her 50s gently holds a Chinese-American newborn in a modern living room. This is the currently growing trend of traditional postpartum care in the United States" The centuries-old tradition of Chinese postpartum confinement is going mainstream in America, as more families seek culturally rooted newborn care and maternal recovery support. LOS ANGELES, CA - August 15, 2025 - The centuries-old practice of zuo yue zi — or Chinese postpartum confinement — is no longer limited to the Asian community. Families across the United States are increasingly hiring Chinese confinement nannies to ensure mothers receive proper rest, nutrition, and newborn care during the critical first 30 to 100 days after birth. 'Postpartum care is about more than changing diapers — it's about a mother's physical healing, emotional stability, and family bonding,' said Stephanie Lin, founder of My Asian Nanny. 'We've seen a 40% increase in inquiries from non-Asian families over the past three years, especially in major metro areas.' The growing interest reflects a wider shift in attitudes toward postpartum recovery, as more parents seek holistic and culturally informed support. Confinement nannies typically provide round-the-clock newborn care, traditional healing meals, lactation support, and gentle postpartum exercises to aid recovery. The trend is supported by research showing that mothers who receive consistent postpartum care report faster physical recovery, lower stress levels, and a reduced risk of postpartum depression. Parents can learn more or request a nanny by completing the Family Registration Intake Form. About My Asian Nanny My Asian Nanny is a U.S.-based referral agency specializing in postpartum confinement nannies and newborn care. Serving families nationwide, the agency connects clients with experienced caregivers who provide round-the-clock support, traditional postpartum meals, and expert newborn handling. Media Contact Company Name: My Asian Nanny Contact Person: Stephanie Lin Email: Send Email Phone: 6269887577 Address: 216 west Garvey Avenue Unit G City: Monterey Park State: CA Country: United States Website:
Globe and Mail
19 hours ago
- Globe and Mail
Certified CME LLC Launches Cosmetic Training Courses in Aesthetic Medicine
Elevate skills and boost practice's success with reimagined CME program. Los Angeles, California--(Newsfile Corp. - August 15, 2025) - CERTIFIED CME, LLC is thrilled to announce CME approved cosmetic training courses. Attendees gathered around patient table observing live procedure Southern Medical Association designates this live activity for a maximum of 15.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Southern Medical Association and Certified CME. The Southern Medical Association is accredited by the ACCME to provide continuing medical education for physicians. Injectable training in action Enhance Skills with 6 Lasers & Energy-Based Devices. Go to for the agenda Become a qualified injector & Learn PDO Threads Insertion Techniques Spanning IPL, Micro-Needling w/RF, Fractional CO2, 1060nm Diode, LP Nd:YAG 1064nm, Pico and Q-Switched Lasers 2 Part Format – Recording & Hands-On Preceptorship Certification Program Part 1: 7 hour recording of an Expert-led Aesthetics Lecture & Live Demonstrations emailed to the participant. Live Recording: Prior to September 6, 2025, Certified CME, LLC will email a link to a live recording that covers essential didactic lectures, technology demonstrations, and injectable training information. The live recording specifically covers: Introduction to Aesthetics / Fitzpatrick Skin Types Laser Physics and Safety Introduction to Intense Pulsed Light (IPL), Hair Removal, Facial Telangectasias, Non-Ablative Skin Rejuvenation and Acne Treatments IPL Live Patient Demonstrations 1060nm Diode Laser for Non-Invasive Body Treatments Body Contouring RF Micro-Needling for Skin Tightening RF Live Patient Demonstrations CO2 - Ablative Lasers including Fractional Technology Vaginal Restoration - Atrophic Vaginitis Fractional CO2 Live Skin Resurfacing Demonstrations Introduction to Long Pulsed Nd:YAG 1064 nm Laser (Hair Removal, Laser Leg Veins, Onychomycosis: Nail Fungus) Introduction to Q-Switched 1064/532 nm Laser (Tattoo Removal, Melasma, Pigmented Lesions, Carbon Facial & Cellulite) Live Patient Demonstrations Microdermabrasion Exfoliation, Oxygenation, Infusion Techniques Live Patient Demonstrations Injectables; Neurotoxins & Dermal Fillers Live Patient Demonstrations Introduction to Threads & Insertion Techniques Treating sun damage successfully Part 2: Hands-On Preceptorship: On September 6, 2025, there will be an immersive hands-on preceptorship that covers everything in the live recording. Attendees are able to bring their own models. Excellent opportunity to see how an aesthetic practice is set up. The full course agenda and topics covered can be found by visiting Tuition is $1049. To register or for any questions, please contact Certified CME, LLC at or go to Tuition includes: Recorded Didactic Session Recorded Live Demonstrations Certificate of Attendance Certification in Aesthetics Hands-On Preceptorship Neurotoxins & Threads 15.5 AMA PRA Category 1 Credits™ About Certified CME: Certified CME promotes the advancement of knowledge, skills, and excellence in the field of aesthetic medicine through education, training, and collaboration. They welcome doctors, nurses, and P.A.s of all specialties to attend their training. Their mission is to provide honest, trustworthy, professional training courses for clinicians seeking to learn aesthetic medicine with the utmost integrity and free of bias and commercial influence. Cannot view this video? Visit: To view the source version of this press release, please visit
Globe and Mail
2 days ago
- Globe and Mail
Tivic Reports Second Quarter 2025 Financial Results
Tivic Health® Systems, Inc. (NASDAQ: TIVC), a diversified immunotherapeutics company, today announced financial results for the second quarter and six months ended June 30, 2025. 'We have established a strong foundation for Tivic's strategic transformation with our expansion into biopharmaceuticals, making us unique in treating disease by addressing both the body's biochemical and bioelectronic systems,' stated Tivic CEO Jennifer Ernst. 'To maximize our focus on the compelling, late-stage clinical pipeline, we have increasingly shifted resources away from consumer healthtech and are now planning to exit the ClearUP business by the end of this year,' continued Ernst. 'I look forward to advancing the commercialization of these life-saving therapies, supporting our strategy to increase shareholder value through this transformation.' Corporate Highlights from the Second Quarter and Subsequent Weeks, included: Securing positive interest in potential military and defense applications for drug candidate Entolimod™ to treat ARS during briefings with the White House and U.S. Food & Drug Administration (FDA) officials. Extending the worldwide license of Entolimod™ to include the treatment of neutropenia, a condition that reduces the body's ability to combat infections and has a wide range of causes - from genetics to cancer treatments and age. Entering into a GMP manufacturing validation agreement with Scorpius Biomanufacturing, Inc. as part of preparing for the FDA biologics license application process. Completing all study visits in the Optimization Study for its patent-pending, non-invasive cervical vagus nerve stimulation (ncVNS) device. Raising $1.4 million from the first and second tranche of a preferred equity purchase agreement that provides for up to $8.4 million in total financing. Entering into a $25 million equity line of credit that generated net proceeds of $547,000. Receiving shareholder approval of key measures in support of Tivic transformation strategy. Expanding biopharmaceutical team with regulatory, clinical and business development staff. Naming Lisa Wolf as CFO following her nine-month tenure as interim CFO. Financial Performance: Revenue (net of returns) for the three and six months ended June 30, 2025 totaled $86,000 and $156,000, respectively, compared with $140,000 and $474,000 for 2024. The decreases are due to lower unit sales of ClearUP™ to treat sinus pain and pressure. The lower sales are attributable to decreases in advertising expenses as the company focused resources on accelerating its TLR5 program for the development of Entolimod™ for ARS. Gross profit in the three and six months ended June 30, 2025 was $54,000 and $104,000, respectively, compared to $30,000 and $197,000 in 2024. Gross margin was 67% in the six months ended June 30, 2025, compared to 42% in 2024. Operating expenses in the three and six months ended June 30, 2025 was $2.0 million and $3.5 million, respectively, compared to $1.3 million and $3.0 million in 2024. The increases were primarily due to the addition of the biopharma programs in February 2025. Net loss of $1.9 million for the three months ended June 30, 2025, compared to $1.3 million in the second quarter of 2024. Net loss of $3.4 million for the first half of 2025, compared to $2.7 million for the first half of 2024. At June 30, 2025, cash and cash equivalents totaled $1.2 million, compared with $2.0 million, at December 31, 2024. Subsequent to quarter's end, the Company raised a total of $0.9 million through utilization of its equity line of credit and the sale of Series B Preferred Stock pursuant to its preferred equity purchase agreement. The company has no debt on its balance sheet. Approximately $7.0 million remains available as a committed investment in Tivic through a preferred equity purchase agreement. The company believes the current and committed funding is sufficient to make meaningful progress toward manufacturing validation for Entolimod. Conference Call and Webcast Information Management will host a webcast/conference call today, Thursday, August 14, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the company's second quarter 2025 financial results and provide a business update. Teleconference Details: Toll Free: 877-545-0523 International: 973-528-0016 Participant Access Code: 793820 Webcast Link An audio replay of the call will be available for the next 90 days from the investor page on the Tivic Health website at About Tivic Tivic's dual platform utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; timing and success of clinical trials and study results; regulatory requirements and pathways for approval; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 'Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. June 30, 2025 December 31, 2024 (Unaudited) (Audited) ASSETS Cash and cash equivalents $ 1,184 $ 2,002 Other current assets 658 637 TOTAL CURRENT ASSETS 1,842 2,639 PROPERTY AND EQUIPMENT, NET 120 119 NONCURRENT ASSETS 2,546 49 TOTAL ASSETS $ 4,508 $ 2,807 LIABILITIES AND STOCKHOLDERS' EQUITY Accounts payable and accrued expenses $ 821 $ 272 TOTAL CURRENT LIABILITIES 821 272 TOTAL LONG-TERM LIABILITIES — — STOCKHOLDERS' EQUITY Preferred stock — — Common stock 1 1 Additional paid in capital 50,661 46,075 Accumulated deficit (46,975 ) (43,541 ) TOTAL STOCKHOLDERS' EQUITY 3,687 2,535 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 4,508 $ 2,807 Tivic Health Systems, Inc. Condensed Statements of Operations (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 REVENUES $ 86 $ 140 $ 156 $ 474 COST OF SALES 32 110 52 277 GROSS PROFIT 54 30 104 197 OPERATING EXPENSES Research and development 655 302 990 558 Sales and marketing 426 207 605 712 General and administrative 907 787 1,949 1,674 TOTAL OPERATING EXPENSES 1,988 1,296 3,544 2,944 NET OPERATING LOSS (1,934 ) (1,266 ) (3,440 ) (2,747 ) OTHER INCOME, NET 3 0 7 0 NET LOSS $ (1,931 ) $ (1,266 ) $ (3,433 ) $ (2,747 ) NET LOSS PER SHARE - BASIC AND DILUTED $ (2.19 ) $ (5.37 ) $ (4.64 ) $ (17.05 ) WEIGHTED-AVERAGE NUMBER OF SHARES - BASIC AND DILUTED 881,294 235,868 739,618 161,103
